Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 9, 2007. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, and Connected Persons regarding their interests in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to insider trading disclosures and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details specific share transactions by the following individuals:
- Dr. J-P Garnier: Exercised options for 68,411 ADSs at $32.09 and sold 51,100 ADSs at an average price of $55.81. Total holding is 556,198 ADSs.
- Mr. J S Heslop: Purchased 10,000 Ordinary shares at GBP14.51 per share. Total holding is 42,204 Ordinary shares.
- Mr. D Phelan: Exercised options for 149,623 ADSs (split between two plans at $40.54 and $37.25) and sold 149,623 ADSs at an average price of $55.81.
- Mr. D Stout: Exercised options for 4,951 ADSs at $32.09 and sold 3,475 ADSs at an average price of $55.87.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document confirms compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total shareholdings of Dr. Garnier, Mr. Heslop, Mr. Phelan, and Mr. Stout as reported in this filing.
- Confirm the exercise prices and sale prices of ADSs to assess the realized gains by directors.
- Note that Mr. Heslop's purchase was made in GBP while other transactions were in USD.
- Review the specific share option plans (SmithKline Beecham 1991 and GlaxoSmithKline 2002) referenced for option grants.